GE HealthCare to Snap Up Sofie Biosciences for $945M
GE HealthCare agreed to acquire Sofie Biosciences for $945M, expected to close by mid-2027. The deal aims to bolster GE's radiopharmaceutical market position, adding US manufacturing and distribution for PET products. Sofie's FAPI-74 rights in the US are included. GE HealthCare projects revenue and earnings growth from the acquisition, with analyst Ryan Zimmerman calling it infrastructure-focused. This follows Curium's $7B acquisition of Lantheus in August.
How this was made
The 30-second read
Why it matters
The deal adds manufacturing and distribution assets, as well as a late‑stage oncology tracer, which could drive incremental revenue and improve supply reliability.
Market read
First‑report $945M acquisition by a major U.S. health‑care firm, likely to influence GEHC's stock and the broader radiopharma sector.
What to watch
Regulatory approval timelines for the Phase III FAPI-74 tracer and potential competition from other PET manufacturers.
Background
GE HealthCare is expanding its radiopharmaceutical portfolio to address supply bottlenecks in PET imaging, a high‑growth niche within nuclear medicine.
Ticker impact
GE HealthCare announced it will acquire Sofie Biosciences for about $945 million, a deal that will add U.S. PET manufacturing capacity and a Phase III radiotracer asset.
potential modest upside as the market prices in the revenue‑boosting and supply‑chain benefits of the deal
First‑report M&A of sub‑$1B scale involving a large, listed health‑care equipment company; investors typically react positively to strategic capacity expansions.
Market effects
Strengthens GE HealthCare's position in the growing radiopharmaceutical market and may pressure peers lacking U.S. manufacturing capacity.
Adds U.S. PET production capability, potentially benefiting North American hospitals and imaging centers.
Highlights consolidation in the global radiopharma supply chain, a trend watched by investors in healthcare and biotech.
Counterpoint
The acquisition could stretch GEHC's integration capacity and dilute focus on its core equipment business, weighing on margins.
Key entities
- CompanyGE HealthCare
U.S.-listed health‑care equipment and services provider (ticker GE).
- CompanySofie Biosciences
Private radiopharmaceutical developer focused on PET production.
